cliexa's Patent Allowance for Evidence-Based Clinical Data Collection & Processing

Today, we are proud to announce that the United States Patent and Trademark Office has announced the issuance of U.S Patent Number 14,243,549 for cliexa’s “System and Methods for Disease Management.” This patent covers clinical data collection and processing using an “Evidence-Based Data Indexing” (EBDI) model which is the core function of cliexa’s modular digital intake and remote monitoring platform. cliexa enables clinicians to monitor patients’ disease activities and clinical outcomes based on standard and dynamic thresholds within treatment workflows. The platform is tailored by subspecialties and provides automated compliance and billing outputs through cliexa’s proprietary integration services engine.

Disease activity is collected digitally through clinically-validated assessments and stored in a discrete format. This data indexing is generated by a proprietary algorithm referencing connected device data, claims data, and medication adherence or complications. Dynamic stored procedures use a new algorithm every time to update the patient-reported outcome assessments in the database and the application server would process the new or multiple assessments to be enabled in mobile front-end to collect data differently to be able to predict risk factors for specific demographics and multiple chronic disease states. Our computing objects get smarter using a learning algorithm by not only comparing the multiple disease data but also the treatment responses from patients and dynamically changing treatments by their clinicians.

Patients are also presented this dynamic data (e.g. what status their disease at compared to millions of other patients with two or more chronic conditions) to become self-advocates of their care and included IoT data also feeds back to the storage service with smart computing objects to compare existing patient data with others already in the system to give an informed picture to the clinicians.

“We are extremely excited to start 2020 with this recognition by the U.S. Patent Office. As clinical data collection and analysis become more powerful every day for the healthcare industry, cliexa’s model leverages proprietary learning algorithms and AI infrastructure, managing multiple conditions by connecting patients to their providers more effectively,” said Mehmet Kazgan, Founder & CEO of cliexa.

Researchers Receive $1 Million Grant to Study Digital Screening Intervention Tool for Adolescents and Young Adults

cliexa is excited to partner with the University of Northern Colorado (UNC) with a grant from the Department of Health and Human Services’ Office of Adolescent Health that provides nearly one million dollars over the next two years for the implementation of cliexa-OPTIONS, a digital screening intervention tool that fosters earlier identification of high-risk adolescents in a clinical setting. The funding supports independent evaluation including, cost-benefit analysis and randomized controlled trial of the cliexa-OPTIONS risk screening tool and MyPLAN mobile health follow-up. The Principal Investigator for the project at UNC is Dr. William Merchant. He is the evaluation professor in the Applied Statistics and Research Methods program in the College of Education and Behavioral Sciences. 

The cost-benefit analysis assesses cost savings between the cliexa-OPTIONS risk screening against current paper pencil and verbal screenings. Also, the cliexa-OPTIONS risk screening identifies 30- 50% more risk in adolescent populations fostering early identification of adolescents at highest risk for acquiring an STI or experiencing an unplanned pregnancy. Improving quality in clinical workflows for adolescent and young adult populations is timely, given that sexually transmitted infections for young people ages 15 -24 are at epidemic proportions.

Saving time and keeping providers satisfied with new technology in clinical workflows is no simple task. The cost-benefit analysis will also assess the benefits of early identification of adolescents at highest risk for adverse reproductive health outcomes, substance use, mental health, and wellness.

Read the full article at: //www.unco.edu/news/newsroom/releases/million-dollar-grant-digital-screening-intervention-tool.aspx

cliexa PTSI Press Release

We are proud to announce that we have officially joined forces with Preventative Technology Solutions, who will now become apart of the cliexa family.

Here is the link to the press release about the acquisition: //www.pr.com/press-release/768313

 

Digital health benefits

2018 has seen a significant boom in the application of technology in digital health innovation, which are poised to disrupt the healthcare industry. Innovations have included advances in mobile health (mHealth), health information technology (IT), as well as wearable and Internet-of-Things (IoT) devices.

cliexa has identified six specific areas of medicine already reaping the benefits of digital health innovation:

1. Rheumatology

Disease Activity Scoring (DAS) metrics remotely collected by cliexa from patients are used by physicians in their offices when assessing the severity of rheumatoid arthritis through a Q & A approach. cliexa empowers patients with the ability to communicate their patient-reported outcomes to their physicians at the touch of a finger, on their own mobile devices, providing physicians with instantly-scored clinically-validated assessments. The application of cliexa innovations in rheumatology drastically increases the efficiency and quality-of-care for both patients and their providers.

Check out the cliexa mobile platform for Rheumatoid Arthritis, cliexa-RA: //www.cliexa.com/cliexamobile/rheumatoid-arthritis/

2. Pain Management, Primary Care, & Integrative Medicine

Chronic pain, affecting over 10% of American adults, is a leading cause of opiate abuse. Managing and overcoming chronic pain is a complex obstacle for many healthcare providers. With the increased shift away from the prescribing of opioids in the treatment of chronic pain, cliexa enables providers to remotely monitors opioid-prescribed patients while empowering them to relay their patient-reported outcomes and track their mental health conditions in association with their chronic pain, while catering specifically towards the individual needs of each patient-provider relationship.

Check out the cliexa mobile platform for Pain Management, cliexa-EASE: //www.cliexa.com/cliexamobile/pain-management/

3. Behavioral Health & Addiction Treatment

Though struggles with addiction are becoming increasingly more prevalent in society, the present methods of addiction treatment are limited. Through innovations in health technologies, patients and providers are shifting towards new ways of treating addiction. The monitoring of patients in real-time is essential for positive treatment outcomes for both patients and their providers. By leveraging patient-reported data, patients adhere to their treatment plans and overcome addiction as a disease, rather than as a fault.

Check out the cliexa mobile platform for Behavioral Health, cliexa-SENSE: //www.cliexa.com/cliexamobile/behavioral-health/

4. Digestive Health

Through cliexa innovations, providers better manage chronic gastrointestinal diseases, such as inflammatory bowel disease or ulcerative colitis, using specifically-designed, highly-structured treatment plans that leverage disease activity scoring models taken from qualitative patient responses to assessments which quantify and track symptoms over long periods of time.

Check out the cliexa mobile platform for Digestive Health, cliexa-IBD: //www.cliexa.com/cliexamobile/inflammatory-bowel-disease/

5. Respiratory Care

cliexa enables providers to qualitatively track chronic diseases of the respiratory system, like chronic obstructive pulmonary disease (COPD), through remote patient-reported outcomes. The ability to structure individualized and specialized care leads to improved patient-provider experiences.

Check out the cliexa mobile platform for Respiratory Care, cliexa-COPD: //www.cliexa.com/cliexamobile/chronic-obstructive-pulmonary-disease/

6. Pediatric Care

cliexa health technology drives innovations in mental health resiliency in adolescents, a hot topic in today’s health community. cliexa’s clinically validated medical assessment applications, coupled with its mHealth prevention services, help providers identify and reduce risk behaviors in adolescents and young adults. cliexa’s mobile patient-engagement applications equip providers with the tools adolescents use to overcome anxiety and depression, increasing the overall quality-of-care for both patients and providers.

Check out the cliexa mobile platform for Pediatric Care, cliexa-OPTIONS: //www.cliexa.com/cliexamobile/adolescent-resiliency/

cliexa at Health:Further 2018

On August 27-29, members of the cliexa team, including founder and CEO Mehmet Kazgan, will be attending the Health:Further Conference in Nashville, TN.

The cliexa booth will be in Entrepreneur’s Alley to demo our platforms, and solutions. Angie Buckley, our Director of Business Development, and Ashley Darnell, our Product Manager, are experts at everything cliexa, and will be there everyday. Don’t be shy, come say hello!

This annual healthcare innovation conference is expected to bring in over 2,000 attendees from various healthcare companies, start-ups, and many investors. Health:Further was started in 2015 by Jumpstart Foundry, who selected cliexa as one of their 2018 portfolio companies. cliexa will be accompanied by other avant-garde companies at the conference, such as Vend.RX, Doc&I, LevelTherapy, and more!

If you are attending the conference, we’d love to meet you, and help you learn more about what we do! Find us on the Health:Further mobile app, and reach out to us through direct message. Our team will be available to answer questions. If you cannot find us at the conference, or will not be attending and still want to learn more about what we do, please feel free to contact us! Hope to see you there!